After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

Novavax’s shot is the only protein-based COVID vaccine available in the U.S. Until now, it had only been allowed for emergency use in people 12 and up. Unlike the mRNA vaccines from Pfizer and Moderna,